Background
==========

About ten percent of breast cancer patients have a history of multiple breast cancer cases in their family, suggesting the inheritance of breast cancer susceptibility alleles in these families. Germline mutations in the *BRCA1*and *BRCA2*genes are identified in about one quarter of the families with breast cancer. Female carriers of *BRCA1*and *BRCA2*mutations have an estimated 50--90% life-time risk to develop breast cancer, classifying both genes as high-risk susceptibility genes \[[@B1],[@B2]\]. Other high-risk breast cancer genes include the *p53*, *PTEN*and *STK11*genes, but mutations in these genes account for only few familial breast cancers. *CHEK2*was the first moderate-risk breast cancer gene being identified \[[@B3]-[@B5]\]. Germline mutations in *CHEK2*are identified in up to 5% of breast cancer families, albeit that their prevalence varies widely among populations. Female carriers of *CHEK2*mutations have a moderate two to three fold increased risk to develop breast cancer. By now, several other moderate-risk breast cancer genes have been identified, including *ATM*, *BRIP1*and *PALB2*\[[@B6]-[@B9]\]. Mutations in these genes all confer increased breast cancer risks of two to three fold and mutations in each of these genes are identified in about 1% of the familial breast cancers. Recently, the international breast cancer association consortium (BCAC) has conducted a large genome-wide association study and identified five single nucleotide polymorphisms (SNPs) that associated with breast cancer \[[@B10]\]. Four of these SNPs were within haplotype blocks that contained genes: SNP rs2981582 locates in intron 2 of the *FGFR2*gene at chromosome 10q; SNP rs889312 locates near *MAP3K1*at 5q; SNP rs3803662 locates between *TNRC9*and the LOC643714 gene at 16q; and SNP rs3817198 locates intronic in *LSP1*at 11p. SNP rs13281615 locates at 8q24 in a region without any annotated genes. Importantly, independent genome-wide association studies have associated other SNPs in *FGFR2*with breast cancer \[[@B11],[@B12]\]. As *FGFR2*had already been implicated in breast cancer \[[@B13]-[@B20]\], the significance of the *FGFR2*SNPs as susceptibility alleles seemed evident. The *TNRC9*SNP had also been associated with breast cancer in another study \[[@B21]\]. Lastly, the 8q24 SNP was of particular interest because other SNPs at 8q24 had been associated with increased risks of prostate cancer and colorectal cancer \[[@B22]-[@B26]\]. BCAC estimated that each of the five identified SNPs associated with rather small increased breast cancer risks, ranging from just over 1.0 to 1.3 fold, classifying them as low-risk susceptibility alleles \[[@B10]\]. However, these low-risk SNPs are very common and their impact is therefore still substantial, together accounting for almost 5% of the familial breast cancers.

The mechanism by which the low-risk susceptibility alleles confer breast cancer risks was obscure \[[@B10]\]. In analogy with the high-risk and moderate-risk breast cancer genes, it had been anticipated that the identified SNPs associated with disease-causing alleles in the coding sequences of nearby located genes. However, extensive sequencing efforts have not identified such alleles in the SNP-associated haplotype blocks, suggesting that the SNPs themselves might be the disease-causing susceptibility alleles \[[@B10]\]. BCAC therefore proposed an alternative disease mechanism that involves expression modulation of genes located in the vicinity of the identified SNPs, thereby conferring low breast cancer risks. Here, we have evaluated expression modulation in a well-characterized cohort of 40 human breast cancer cell lines, allowing us to specifically address whether this mechanism might operate in breast cancer cells.

Methods
=======

Breast cancer cell lines
------------------------

The 40 human breast cancer cell lines used in this study are listed in Table [1](#T1){ref-type="table"} and have been described in detail elsewhere \[[@B27]\]. Microsatellite analysis with nearly 150 polymorphic markers had shown that all cell lines are unique and monoclonal \[[@B28]\].

###### 

Genotypes of five low-risk SNPs in 40 human breast cancer cell lines

  Breast cancer cell lines       SNP genotypes and allelic losses                                                           
  ------------------------------ ---------------------------------- ----- ------- ----- ------- ----- ------- ----- ------- -----
  SUM185PE                       Het                                No    Het     No    Maj H   nd    Min H   nd    Maj H   nd
  BT483                          Het                                No    Maj H   No    Min H   Yes   Maj H   No    Maj H   No
  MDA-MB-134VI                   Het                                No    Het     No    Het     No    Het     No    Maj H   No
  MDA-MB-175VII                  Het                                No    Min H   No    Het     No    Het     No    Maj H   No
  MDA-MB-415                     Het                                No    Het     No    Min H   Yes   Het     No    Het     No
  MPE600                         Het                                No    Maj H   nd    Het     No    Maj H   nd    Het     No
  SUM52PE                        Maj H                              nd    Maj H   nd    Maj H   nd    Maj H   nd    Maj H   nd
  CAMA-1                         Het                                No    Het     No    Min H   No    Maj H   Yes   Maj H   Yes
  MCF-7                          Maj H                              No    Het     No    Maj H   No    Het     No    Maj H   Yes
  ZR75-1                         Het                                No    Het     No    Min H   Yes   Maj H   Yes   Het     No
  SUM44PE                        Het                                No    Min H   nd    Maj H   nd    Het     No    Min H   nd
  T47D                           Het                                No    Het     No    Maj H   No    Min H   Yes   Min H   Yes
  MDA-MB-361                     Het                                No    Het     No    Maj H   No    Het     No    Min H   No
  BT474                          Het                                No    Maj H   No    Maj H   Yes   Maj H   No    Maj H   No
  UACC812                        Min H                              No    Min H   No    Het     No    Het     No    Min H   Yes
  ZR75-30                        Maj H                              nd    Min H   nd    Min H   nd    Min H   nd    Maj H   nd
  OCUB-F                         Maj H                              nd    Maj H   nd    Min H   nd    Min H   nd    Maj H   nd
  SK-BR-5                        Het                                No    Maj H   nd    Min H   nd    Min H   nd    Maj H   nd
  SUM190PT                       Min H                              nd    Min H   nd    Maj H   nd    Min H   nd    Maj H   nd
  SUM225CWN                      Het                                No    Maj H   nd    Maj H   nd    Maj H   nd    Het     No
  MDA-MB-330                     Het                                No    Min H   Yes   Min H   Yes   Het     No    Maj H   No
  MDA-MB-453                     Het                                No    Het     No    Min H   Yes   Maj H   Yes   Maj H   Yes
  SK-BR-3                        Min H                              Yes   Het     No    Het     No    Maj H   Yes   Min H   No
  EVSA-T                         Min H                              nd    Min H   nd    Maj H   nd    Maj H   nd    Min H   nd
  UACC893                        Maj H                              No    Maj H   No    Maj H   Yes   Het     No    Maj H   No
  BT20                           Min H                              No    Maj H   Yes   Maj H   Yes   Maj H   Yes   Het     No
  HCC1937                        Het                                No    Min H   nd    Het     No    Het     No    Maj H   nd
  MDA-MB-468                     Maj H                              Yes   Maj H   Yes   Maj H   Yes   Maj H   Yes   Maj H   Yes
  SUM149PT                       Min H                              nd    Het     No    Min H   nd    Min H   nd    Maj H   Yes
  SUM229PE                       Maj H                              nd    Maj H   nd    Maj H   nd    Maj H   nd    Min H   nd
  BT549                          Maj H                              No    Maj H   No    Maj H   Yes   Het     No    Min H   Yes
  Hs578T                         Het                                No    Maj H   Yes   Min H   Yes   Min H   No    Maj H   No
  MDA-MB-157                     Maj H                              No    Maj H   Yes   Maj H   Yes   Min H   No    Maj H   Yes
  MDA-MB-231                     Maj H                              Yes   Het     No    Het     No    Maj H   Yes   Het     No
  MDA-MB-436                     Maj H                              Yes   Maj H   Yes   Maj H   No    Min H   No    Maj H   Yes
  SK-BR-7                        Het                                No    Het     No    Min H   nd    Maj H   nd    Het     No
  SUM159PT                       Maj H                              nd    Het     No    Min H   nd    Het     No    Maj H   nd
  SUM1315MO2                     Het                                No    Maj H   nd    Min H   nd    Het     No    Maj H   nd
  SUM102PT                       Het                                No    Het     No    Maj H   nd    Het     No    Maj H   nd
  MDA-MB-435s                    Maj H                              No    Maj H   Yes   Maj H   Yes   Maj H   Yes   Maj H   No
                                                                                                                            
  *Total major homozygotes*      13                                       17            19            16            25      
  *Total heterozygotes*          21                                       15            7             14            7       
  *Total minor homozygotes*      6                                        8             14            10            8       
  *Percentage of allelic loss*                                      13            25            52            32            37

Genotypes of five low-risk SNPs have been determined in the current study. Allelotype data have been reported elsewhere and involved microsatellite analysis. Loss: Yes, allelic loss at the indicated chromosomal region; and No, no allelic loss at the indicated chromosomal region. nd, not determined; Maj H, major homozygotes; Min H, minor homozygotes; Het, heterozygote allele carriers.

Genotyping
----------

Genotypes of five low-risk susceptibility alleles have been determined: rs889312 (A\>C) near the *MAP3K1*gene; rs2981582 (C\>T) in the *FGFR2*gene; rs3803662 (C\>T) near the *TNRC9*gene; rs3817198 (T\>C) in the *LSP1*gene and rs13281615 (A\>G) that located in a gene desert at chromosome 8q24 \[[@B10]\]. Genotyping was performed by direct sequencing of PCR-amplified genomic templates, using the BigDye Terminator V3.1 Cycle Sequencing Kit (Applied Biosystems) and an ABI 3130xL Genetic Analyzer. Primer sequences are available upon request.

Allele frequencies of cases and controls reported by BCAC have been obtained by using their reported Odds Ratio data \[[@B10]\], and inferring allele frequencies by assuming that Odds Ratios reflect the ratio of minor allele carriers versus major allele carriers from the cases divided by the ratio of minor allele carriers versus major allele carriers from the controls.

Expression analysis
-------------------

Transcript expression levels of four genes have been determined: *MAP3K1*, *FGFR2*, *TNRC9*and *LSP1*. Quantitative real-time PCR (qPCR) was performed on cDNA templates that had been generated with oligo-dT and random hexamer primers from total RNA isolates, using *Power*SYBR Green PCR Master Mix (Applied Biosystems) and an ABI Prism 7700. Ct values were normalized according *HPRT*and *HMBS*housekeeper Ct values. Transcript expression had also been determined by Human Exon 1.0 ST microarrays (Affymetrix), as described elsewhere \[[@B29]\]. The exon array data have been deposited in NCBI\'s Gene Expression Omnibus \[[@B30]\] and are accessible through GEO Series accession number GSE16732.

Statistical analysis
--------------------

Statistical analyses were performed with Statistical Package for the Social Sciences (SPSS) version 11.5, considering P-values of less than 0.05 significant. Fisher\'s exact test was used to determine association of the SNP genotypes with the breast cancer cell lines. The Kruskal Wallis test was used to compare gene expression levels among three SNP genotype groups (major homozygotes, heterozygotes, and minor homozygotes).

Results and discussion
======================

Genotyping of low-risk susceptibility alleles in breast cancer cell lines
-------------------------------------------------------------------------

Genotypes of five low-risk susceptibility alleles \[[@B10]\] were determined in a cohort of 40 human breast cancer cell lines. For each SNP, frequencies of major homozygotes, heterozygotes and minor homozygotes are shown in Figure [1a](#F1){ref-type="fig"} and genotypes are detailed in Table [1](#T1){ref-type="table"}. Frequencies of homozygote genotypes typically were higher than anticipated, likely related to allelic losses in the cell line samples (Figure [1a](#F1){ref-type="fig"}; \[[@B10]\]). For four SNPs (*8q24*, *MAP3K1*, *FGFR2*and *TNRC9*), the minor allele frequencies among the cell lines were higher than among the 21,860 BCAC breast cancer cases and 22,578 population controls (Figure [1b](#F1){ref-type="fig"}; \[[@B10]\]). Fisher\'s exact testing indicated that the minor allele frequencies among the cell lines were significantly higher than the BCAC population controls for two SNPs: *MAP3K1*and *TNRC9*(Figure [1b](#F1){ref-type="fig"}). In Table [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, we also included previously-determined phenotypic and genotypic data on the breast cancer cell lines, including data on molecular subtyping and allelotyping (Hollestelle *et al*. submitted for publication; \[[@B28]\]). Together with the SNP genotypes, we provide a base line for functional studies in this cohort of breast cancer cell lines.

![**Genotypes and minor allele frequencies of five low-risk breast cancer susceptibility alleles or SNPs in human breast cancer cell lines**. **1a**. Gray bars represent SNP genotype frequencies of 21,860 blood-derived samples from breast cancer cases reported by the breast cancer association consortium BCAC \[[@B10]\], and white bars represent genotype frequencies in 40 breast cancer cell lines. Maj H, major homozygotes; Min H, minor homozygotes; and Het, heterozygote allele carriers. The major and minor alleles of each allele are indicated between brackets. **1b**. Black and gray bars represent minor allele frequencies in 22,578 population controls and 21,860 breast cancer cases, respectively, as reported by BCAC \[[@B10]\]. White bars represent frequencies identified in 40 breast cancer cell lines.](1471-2407-9-236-1){#F1}

###### 

Molecular and phenotypic characterizations of 40 breast cancer cell lines

  Breast cancer cell lines      Breast cancer subtype   Intrinsic subtype   Protein expression             
  ----------------------------- ----------------------- ------------------- -------------------- ---- ---- ----
  SUM185PE                      Luminal-type            Luminal             \-                   \-   \-   \+
  BT483                         Luminal-type            Luminal             \+                   \-   \+   \-
  MDA-MB-134VI                  Luminal-type            Luminal             \+                   \-   \-   \-
  MDA-MB-175VII                 Luminal-type            Luminal             \+                   \-   \-   \-
  MDA-MB-415                    Luminal-type            Luminal             \+                   \-   \-   \-
  MPE600                        Luminal-type            Luminal             \+                   \-   \+   \-
  SUM52PE                       Lumina-type             Luminal             \+                   \-   \+   \-
  CAMA-1                        Lumina-type             Luminal             \+                   \+   \+   \-
  MCF-7                         Luminal-type            Luminal             \+                   \+   \-   \-
  ZR75-1                        Luminal-type            Luminal             \+                   \+   \+   \-
  SUM44PE                       Luminal-type            Luminal             \+                   \+   \-   \-
  T47D                          Luminal-type            Luminal             \+                   \+   \-   \-
  MDA-MB-361                    Luminal-type            Luminal             \+                   \+   ++   \-
  BT474                         Luminal-type            Luminal             \-                   \+   ++   \-
  UACC812                       Luminal-type            Luminal             \-                   \+   ++   \-
  ZR75-30                       Luminal-type            Luminal             \+                   \-   ++   \-
  OCUB-F                        Luminal-type            Luminal             \-                   \-   ++   \-
  SK-BR-5                       Luminal-type            Luminal             \-                   \-   ++   \-
  SUM190PT                      Luminal-type            nd                  \-                   \-   ++   \-
  SUM225CWN                     Luminal-type            nd                  \-                   \-   ++   \-
  MDA-MB-330                    Luminal-type            ERBB2               \+                   \-   ++   \-
  MDA-MB-453                    Luminal-type            ERBB2               \-                   \-   ++   \-
  SK-BR-3                       Luminal-type            ERBB2               \-                   \-   ++   \-
  EVSA-T                        Luminal-type            ERBB2               \-                   \-   ++   \-
  UACC893                       Luminal-type            ERBB2               \-                   \-   ++   \-
  BT20                          Basal-type              Basal-like          \-                   \-   \-   \+
  HCC1937                       Basal-type              Basal-like          \-                   \-   \-   \+
  MDA-MB-468                    Basal-type              Basal-like          \-                   \-   \-   \+
  SUM149PT                      Basal-type              Basal-like          \-                   \-   \-   \+
  SUM229PE                      Basal-type              Basal-like          \-                   \-   \-   \+
  BT549                         Basal-type              Normal-like         \-                   \-   \-   \+
  Hs578T                        Basal-type              Normal-like         \-                   \-   \-   \+
  MDA-MB-157                    Basal-type              Normal-like         \-                   \-   \-   \+
  MDA-MB-231                    Basal-type              Normal-like         \-                   \-   \-   \+
  MDA-MB-436                    Basal-type              Normal-like         \-                   \-   \-   \+
  SK-BR-7                       Basal-type              Normal-like         \-                   \-   \-   \+
  SUM159PT                      Basal-type              Normal-like         \-                   \-   \-   \+
  SUM1315MO2                    Basal-type              Normal-like         \-                   \-   \-   \+
  SUM102PT                      Basal-type              Normal-like         nd                   nd   nd   nd
  MDA-MB-435s                   Basal-type              Normal-like         \-                   \-   \-   \+
                                                                                                           
  *Total phenotype positives*                                               14                   8    13   16

Phenotypic characterizations have been reported elsewhere and involved protein expression patterns of the cell lines for the breast cancer subtyping (cytokeratins, ER, PgR and ERBB2) and expression of the intrinsic gene set for the intrinsic subtyping (Hollestelle *et al*. submitted for publication). Protein expression: +, expressed; ++, over expressed; and -, not detectable; 3-neg, triple-negative.

Expression levels of nearby located genes in breast cancer cell lines do not correlate with their SNP genotype
--------------------------------------------------------------------------------------------------------------

Surprisingly, BCAC had not identified disease-causing gene variants within the haplotype blocks of the five low-risk SNPs \[[@B10]\]. They proposed an alternative disease mechanism, in which SNP genotypes modulate expression levels of nearby located genes. Such disease mechanism was conceivable because the minor SNP alleles confer only low risks for breast cancer. Here, we have evaluated whether gene expression modulation is operative in breast cancer cell lines, by associating SNP genotypes of the breast cancer cell lines with the expression levels of nearby located genes.

Gene expression data of the four genes physically nearest to the SNPs were obtained by Affymetrix Human Exon 1.0 ST microarray profiling and by qPCR analysis. Both transcript expression analysis methods revealed similar expression levels for each of the four genes: *MAP3K1*, *FGFR2*, *TNRC9*and *LSP1*, with Spearman correlation coefficients of -0.6, -0.7, -0.8 and -0.4, respectively, among the 40 breast cancer cell lines (Table [3](#T3){ref-type="table"} and Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). Because BCAC had shown that the low-risk SNPs confer breast cancer risks in a dose-dependent manner, with the highest risks for the minor homozygotes \[[@B10]\], association between gene expression levels and SNP genotypes was performed by three-group comparisons. Exon array data are shown in Figure [2](#F2){ref-type="fig"}, with cell lines from each genotype group depicted in a different color. Unique outliers typically represented decreased expression of one or more probes sets, such as exon 17 of *MAP3K1*or exons 3--5 of *TNRC9*, possibly related to the presence of SNPs in probe sequences, alternative splicing or genomic deletions \[[@B29]\]. Expression of recurrent isoforms as reported by NCBI was detected only for the *FGFR2*gene, with two cell lines expressing the isoform that lacked exon 9. Both cell lines were minor homozygotes for the *FGFR2*SNP. Overall, there was no apparent association between the exon array expression level of each of the four genes and their SNP genotypes (Figure [2](#F2){ref-type="fig"}). The qPCR Ct-values are detailed in Table [3](#T3){ref-type="table"} and the three-group comparisons are shown in Figure [3](#F3){ref-type="fig"}. Again, we did not detect any association between gene expression levels with SNP genotypes for the four genes. It is possible that gene expression levels are affected by allelic loss of the gene loci. We therefore also have compared gene expression levels in major and minor homozygotes with allelic loss to the gene expression levels in cell lines without allelic loss, but gene expression levels did not correlate with allelic losses either (Table [4](#T4){ref-type="table"}). Altogether, these results strongly suggest that a putative disease mechanism by expression modulation does not operate via cancer cells. Yet, recent studies have shown that expression levels of the *FGFR2*, *MAP3K1*and *TNRC9*genes associated with their SNP genotype in clinical breast cancer samples \[[@B31],[@B32]\]. It may be that expression modulation is operative in non-neoplastic stromal or epithelial cells and perhaps only early in carcinogenesis. Alternatively, it may be that expression modulation of these genes was operative in invasive breast cancer cells but was lost upon *in vitro*propagation of the cell lines. Expression analysis of carefully dissected tumor cells and non-neoplastic epithelial and stromal cells from clinical breast cancer samples should resolve this issue and may determine the precise mechanism of expression modulation by low-risk breast cancer susceptibility alleles.

![**Normalized expression levels from Affymetrix Human Exon 1.0 ST microarrays of 2a. *MAP3K1*; 2b. *FGFR2*; 2c. *TNRC9*; and 2d. *LSP1*; from 40 human breast cancer cell lines**. Kruskal Wallis testing using the average expression among all probe sets for each gene did not reveal significant associations between gene expression and SNP genotypes. Each line represents a cell line, with the color-coding according the genotype groups: green, major homozygotes; red, minor homozygotes; and blue, heterozygotes. Two cell lines with the delEx9 isoform of *FGFR2*are indicated with bold red lines. Probe sets for each gene were ordered by physical location and indicated by exon, where probe sets that were not unique for that gene were omitted. Probe sets with expression values less than the background of 50 were also omitted, unless more than 3 cell lines had expression levels higher than 100.](1471-2407-9-236-2){#F2}

![**Correlation of gene expression levels of 3a. *MAP3K1*; 3b. *FGFR2*; 3c. *TNRC9*; and 3d. *LSP1*; with the SNP genotypes in 40 human breast cancer cell lines**. Kruskal Wallis testing did not reveal any significant association between gene expression and SNP genotypes. Maj H, major homozygotes; Min H, minor homozygotes; and Het, heterozygote allele carriers. The number of cell lines in each genotype group is indicated under the genotypes and data are detailed in Table 1.](1471-2407-9-236-3){#F3}

###### 

Gene expression analysis of *MAP3K1, FGFR2*, *TNRC9*and *LSP1*in 40 human breast cancer cell lines by quantitative RT-PCR, represented by normalized Ct values

  Breast cancer cell lines                  Transcript expression (normalized Ct values)             
  ----------------------------------------- ---------------------------------------------- ---- ---- ----
  BT20                                      23                                             30   45   38
  BT474                                     24                                             35   22   35
  BT483                                     22                                             31   25   36
  BT549                                     29                                             32   39   40
  CAMA-1                                    24                                             33   26   45
  EVSA-T                                    25                                             33   25   45
  HCC1937                                   26                                             32   37   45
  Hs578T                                    26                                             45   45   34
  MCF-7                                     25                                             34   28   39
  MDA-MB-134VI                              22                                             37   24   35
  MDA-MB-157                                25                                             44   33   29
  MDA-MB-175VII                             24                                             35   23   36
  MDA-MB-231                                26                                             45   45   35
  MDA-MB-330                                26                                             32   27   33
  MDA-MB-361                                23                                             34   23   44
  MDA-MB-415                                23                                             28   20   33
  MDA-MB-435s                               25                                             45   45   45
  MDA-MB-436                                26                                             35   31   37
  MDA-MB-453                                24                                             36   29   45
  MDA-MB-468                                25                                             35   37   37
  MPE600                                    23                                             31   22   42
  OCUB-F                                    23                                             39   23   42
  SK-BR-3                                   25                                             32   26   37
  SK-BR-5                                   23                                             37   21   43
  SK-BR-7                                   26                                             39   45   35
  SUM102PT                                  25                                             35   32   29
  SUM1315M02                                26                                             43   44   35
  SUM149PT                                  27                                             38   45   37
  SUM159PT                                  27                                             45   43   34
  SUM185PE                                  23                                             38   23   45
  SUM190PT                                  24                                             45   23   45
  SUM225CWN                                 24                                             36   23   39
  SUM229PE                                  25                                             39   33   36
  SUM44PE                                   22                                             41   26   36
  SUM52PE                                   24                                             24   24   37
  T47D                                      20                                             36   45   35
  UACC812                                   24                                             38   24   45
  UACC893                                   21                                             36   25   36
  ZR75-1                                    24                                             36   24   32
  ZR75-30                                   23                                             33   23   43
                                                                                                     
  *Total high expressers (Ct \<*20)         1                                              0    1    0
  *Total moderate expressers (Ct 20--30)*   39                                             2    23   2
  *Total low expressers (Ct \>*30--35)      0                                              12   4    5
  *Total no expressers (Ct \>*35)           0                                              26   12   33

###### 

Gene expression of *MAP3K1*, *FGFR2*, *TNRC9*and *LSP1*in human breast cancer cell lines according to their allelic loss status at the gene locus

  -----------------------------------------------------------------------------------------
  Gene       Genotype\                    Average expression level (Normalized Ct values)
             (Number of cell lines)       
  ---------- ---------------------------- -------------------------------------------------
  *MAP3K1*   Het (n = 14)                 24 ± 2

             Maj H no loss (n = 4)        24 ± 4

             Min H no loss (n = 2)        24 ± 0

             Maj H allelic loss (n = 1)   26

             Min H allelic loss (n = 6)   25 ± 1

                                          

  *FGFR2*    Het (n = 7)                  36 ± 5

             Maj H no loss (n = 4)        31 ± 7

             Min H no loss (n = 1)        33

             Maj H allelic loss (n = 6)   35 ± 6

             Min H allelic loss (n = 6)   38 ± 6

                                          

  *TNRC9*    Het (n = 14)                 30 ± 8

             Maj H no loss (n = 2)        24 ± 2

             Min H no loss (n = 3)        36 ± 8

             Maj H allelic loss (n = 1)   45

             Min H allelic loss (n = 7)   36 ± 9

                                          

  *LSP1*     Het (n = 7)                  37 ± 4

             Maj H no loss (n = 8)        37 ± 4

             Min H no loss (n = 2)        41 ± 5

             Maj H allelic loss (n = 3)   40 ± 5

             Min H allelic loss (n = 7)   38 ± 6
  -----------------------------------------------------------------------------------------

Although numbers are small for some sample groups, there are no apparent differences in gene expression levels related to allelic loss status. Allelic loss data and qPCR expression data are detailed in Table 1 and Table 3, respectively. Maj H, major homozygotes; Min H, minor homozygotes; Het, heterozygote allele carriers.

Conclusion
==========

We present the genotypes of five low-risk susceptibility alleles or SNPs of 40 human breast cancer cell lines. Using this cell line model, we have evaluated the BCAC hypothesis that low-risk SNPs confer breast cancer risks by modulation of expression levels of nearby located genes. We found no evidence for expression modulation in the breast cancer cell lines, suggesting that such disease mechanism is more likely to operate in non-neoplastic epithelial or stromal cells or has been lost during *in vitro*propagation of the cell lines.
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